A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Researchers designed a trial medicine called MK‐7262 to lower levels of Lp(a) in theblood. Researchers want to learn about giving MK‐7262 with another trial medicine calledenlicitide (also known as MK‐0616 or enlicitide decanoate). Enlicitide is in a group ofmedicines that lower the amount of low‐density lipoprotein cholesterol (LDL‐C).The goals of this trial are to evaluate: ‐ if MK‐7262 and enlicitide taken together work better than placebo at lowering Lp(a)and LDL‐C levels in the blood ‐ if MK‐7262 alone works better than placebo at lowering Lp(a) levels in the blood ‐ the safety and tolerability of taking MK‐7262 and enlicitide alone and together